

To:

Head of Paediatric Medicines
European Medicines Agency

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): daprodustat

Invented name: NA

Latest Decision number(s): 1) P/0191/2014 2) P/0025/2018 3) P/0047/2021
4) P/0242/2022

Corresponding PIP number(s): 1) EMEA--001452-PIP01-13 2) EMEA-001452-PIP01-13-M01
3) EMEA-001452-PIP01-13-M03 4) EMEA--001452-PIP01-13-M04

Date of initial marketing authorisation granted: NA

Date of authorisation of new indication, pharmaceutical form or route of administration: NA

Please note that development of the medicinal product above in the following
condition(s)/indication(s):

Treatment of anaemia due to chronic disorders

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☐ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☒ commercial reasons (please specify: ease see below))

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☐ other reason (please specify:)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

GlaxoSmithKline Trading Services Limited has taken the decision to withdraw the application for Marketing Authorisation of (daprodustat), 1mg, 2mg, 4mg, 6mg, 8mg immediate release film-coated tablets, which was intended to be used for treatment of anaemia associated with chronic kidney disease (CKD) in adults.

This withdrawal was based on the Committee for Medicinal Products for Human Use (CHMP) recommendation that be authorised for use only in adults on chronic maintenance dialysis (and not in patients not on dialysis) and the implications for the Company's strategy.

The positive Opinion for Jesdubroq was granted at the June 2023 CHMP meeting. Withdrawal of the MAA was acknowledged at the July 2023 CHMP meeting.

Please note that if the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies to the PIP in question:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Name and signature of the PIP contact point: Signature on file

Date: 7 August 2023

Contact for inquiries from interested parties: GlaxoSmithKline Trading Services Limited

Telephone: +1 4388998201

Email: eu.paediatric-plans@gsk.com